OPEN FOR RECRUITMENT

ATOSSA AG-1001-AU-02 STUDY

An Open Label, Pharmacodynamic Study of (Z)-endoxifen in Patients with Invasive Breast Cancer Prior to Undergoing Mastectomy or Lumpectomy.


PHASE II: XENERA-1 BI1280-0022 STUDY

A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2-metastatic breast cancer and non-visceral disease.

Follow this link for further information


PHASE I: ARCUS AB928CSP0002 STUDY

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynaecologic Malignancies.

Follow this link for further information


PHASE III: IMPASSION 030 WO39391 STUDY

A Phase III, Multicentre, Randomized, Open-label Study Comparing

ATEZOLIZUMAB (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy vs Chemotherapy Alone in Patients with Operable Triple-Negative Breast Cancer

Follow this link for further information


 PHASE III: DAIICHI SANKYO DS8201-A-U301 STUDY

A Phase 3, multicentre, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pre-treated with prior standard of care HER2 therapies, including T-DM1.

Follow this link for further information


 PHASE III: DAIICHI SANKYO DS8201-A-U302 STUDY

A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.

Follow this link for further information

BREAST CANCER

ATOSSA AG-1001-AU-02 STUDY

An Open Label, Pharmacodynamic Study of (Z)-endoxifen in Patients with Invasive Breast Cancer Prior to Undergoing Mastectomy or Lumpectomy.


PHASE II: XENERA-1 BI1280-0022 STUDY

A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2-metastatic breast cancer and non-visceral disease.

Follow this link for further information


PHASE I: ARCUS AB928CSP0002 STUDY

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynaecologic Malignancies.

Follow this link for further information


PHASE III: IMPASSION 030 WO39391 STUDY

A Phase III, Multicentre, Randomized, Open-label Study Comparing

ATEZOLIZUMAB (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy vs Chemotherapy Alone in Patients with Operable Triple-Negative Breast Cancer

Follow this link for further information


 PHASE III: DAIICHI SANKYO DS8201-A-U301 STUDY

A Phase 3, multicentre, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pre-treated with prior standard of care HER2 therapies, including T-DM1.

Follow this link for further information


 PHASE III: DAIICHI SANKYO DS8201-A-U302 STUDY

A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.

Follow this link for further information

GASTRO INTESTINAL TUMOURS

PHASE III BOSTON CANSTEM303C CRC STUDY

A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Follow this link for further information


 PHASE I: ARCUS AB928CSP0003 STUDY 

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Gastrointestinal Malignancies.

Follow this link for further information


 PHASE III: SOLSTICE (CL3-95005-006) STUDY

An open-label, randomised, phase III Study comparing trifluridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapy

Follow this link for further information

COLORECTAL CANCER

GASTRIC AND GASTRO-ESOPHAGEAL JUNCTION CANCER

Toggle Content goes here

LUNG CANCER

PHASE I: HMPL-523 HUTCHISON STUDY

A Phase I, open-label, dose-escalation study of the safety and pharmacokinetics of HMPL-523 in patients with relapsed or refractory Hematologic Malignancies

Follow this link for further information


PHASE III: RESILIENT – IPSEN MM-398 STUDY

A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy

Follow this link for further information


PHASE II: TAKEDA BRIGATINIB-2002 STUDY 

Brigatinib in Patients with Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

Follow this link for further information

MYELODYSPLASTIC SYNDROME (MDS)

Toggle Content goes here

PANCREATIC CANCER

Toggle Content goes here

LYMPHOMA

PHASE I: HMPL-523 HUTCHISON STUDY

A Phase I, open-label, dose-escalation study of the safety and pharmacokinetics of HMPL-523 in patients with relapsed or refractory Hematologic Malignancies

PROSTATE CANCER

PHASE II: CO-338-052 TRITON2 STUDY 

A Multicentre, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency.

Follow this link for further information


PHASE III: CO-338-063 TRITON3 STUDY

A Multicentre, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency.

Follow this link for further information

UROTHELIAL

PHASE III: 42756493BLC3001 THOR STUDY

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Follow this link for further information


PHASE II: MK-3475-057STUDY 

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy.

Follow this link for further information

SOLID TUMOURS

PHASE I: ABBVIE M15-862 STUDY

A Multicentre, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927, an Immunotherapy, in Subjects with Advanced Solid Tumours

Follow this link for further information


PHASE I: EnGeneIC ENG8 DESIGNER EDV STUDY 

A Phase 1 Study of Anti-Human EGFR (Vectibix Sequence) Targeted EDVTMs Carrying the Cytotoxic Drug PNU-159682 (EGFR(V)-EDV-PNU) with Concurrent Non-Targeted EDVs Carrying an Immunomodulatory Adjuvant (EDV-40mer) in Subjects with Advanced Solid Tumours who have No Curative Treatment Options.

Follow this link for further information


PHASE I / II: BMS CA030001 STUDY

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumours.

Follow this link for further information


PHASE I / IIa: EnGeneIC CAROLYN ENG 9 STUDY

A Phase I/IIa Study of EGFR-Targeted EDVTMs Carrying the Cytotoxic Drug PNU-159682 (E-EDV-D682) with Concurrent Immunomodulatory Adjuvant Non-Targeted EDVs carrying α-galactosyl ceramide (EDV-GC) in (i) Cohort 1, Subjects with Advanced Pancreatic Cancer and (ii) Cohort 2, Subjects with other EGFR Expressing Solid Tumours, who have Failed First or Second-line Therapy or where other Standard Therapies are not Appropriate

Follow this link for further information


PHASE II: DEBIO 1347-201 FUZE STUDY

A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumours harbouring a fusion of FGFR1, FGFR2 or FGFR3.

Follow this link for further information